NASDAQ:TCRX | Cash Flow Statement | TScan Therapeutics, Inc.

Complete source-backed cash-flow history.

Available history
2020-06-30 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$30.36M
2026-03-31-$28.67M-$24.28M$70,000.00-$70,000.00
2025-12-31-$22.98M-$32M$171,000.00$14.83M$73,000.00
2025-09-30-$35.71M
2025-06-30-$36.95M
2025-03-31-$34.13M-$37.59M$1.53M$13.53M-$525,000.00
2024-12-31-$35.81M-$27.41M$888,000.00$27.29M$45.69M
2024-09-30-$29.89M
2024-06-30-$31.66M
2024-03-31-$30.14M-$29.27M$705,000.00$36.16M$258,000.00
2023-12-31-$19.61M-$23.77M$469,000.00$1.91M$19,000.00
2023-09-30-$23M
2023-06-30-$24.05M
2023-03-31-$22.56M-$23.59M$838,000.00-$838,000.00
2022-12-31-$18.72M-$16.01M$1.38M-$1.38M$108,000.00
2022-09-30-$16.25M
2022-06-30-$15.1M
2022-03-31-$16.16M-$20.12M$531,000.00-$531,000.00$88,000.00
2021-12-31-$14.2M-$14.38M$2.21M-$2.21M$120,000.00
2021-09-30-$15.84M
2021-06-30-$10.67M
2021-03-31-$7.91M-$9.96M$2.96M-$2.96M$99.63M
2020-12-31-$7.81M-$7.35M$1.39M-$1.39M$40,000.00
2020-09-30-$7.17M
2020-06-30-$5.61M

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$129.77M-$135.32M$4.41M$109.37M-$336,000.00
2024-12-31-$127.5M-$110.82M$3.83M-$52.61M$208.77M
2023-12-31-$89.22M-$61.36M$3.15M-$60.76M$135.44M
2022-12-31-$66.22M-$66.5M$4.23M-$4.23M$29.36M
2021-12-31-$48.63M-$48.68M$9.94M-$9.94M$189.67M
2020-12-31-$26.13M-$3.02M$4.24M-$4.24M$288,000.00

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.